Curated news and analysis on clinical trials, drug approvals, and medical research.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Multiple myeloma care is increasingly centered on CAR T-cell therapy and bispecific antibodies, with experts highlighting early evaluation, sequencing, and delivery challenges. Extramedullary disease remains a poor prognostic factor, while new data from the MajesTEC-3 trial show comparable outcomes for the daratumumab–teclistamab combination versus cilta-cel. Access and value-based care initiatives aim to reduce geographic and financial barriers.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
New Mexico House passes three healthcare bills, including medical malpractice reform, expanded loan repayment, and a ban on certain facility fees. All now head to the Senate.
ImmunityBio's Q1 2026 product revenue rose 168% to $44.2 million, beating estimates, while the GAAP net loss widened to $632.8 million. The company is advancing a Phase 2 NHL trial and an sBLA for BCG-naïve NMIBC.
UVA Health found gliomas may be more receptive to focused ultrasound drug delivery. Related research covers miRNA therapy, low-intensity focused ultrasound, and 3D organoid drug testing.
Life Biosciences has treated the first patient with ER-100, a cell-rejuvenating gene therapy for glaucoma. The FDA-approved Phase 1 trial will assess safety in up to 18 patients.
Delaware State Police arrested a Newark man on felony drug charges after a traffic stop in Townsend. Officers seized crack cocaine, cocaine, heroin, and over $2,200 in suspected drug proceeds.
A botanical moisturizer with oat and aloe outperformed metronidazole for rosacea erythema and lesions over 12 weeks. A separate study found nine risk factors for rosacea severity, including female sex, family history, and skin care habits.
FDA's advisory committee voted 9-0 that Moderna's mRNA flu vaccine mFlusiva benefits outweigh risks for adults 50-64 and 65+, clearing a key hurdle before an Aug. 5, 2026 decision. The FDA initially declined to review the BLA before reversing course.
Prothena Corporation plc will report its second quarter and first six months of 2026 financial results on August 6, 2026, after U.S. market close. No conference call will be held, consistent with past practice. The company focuses on neurodegenerative and rare amyloid diseases.
Benchmark studies show general-purpose LLMs like GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6 outperform FDA-cleared clinical AI tools and physicians on diagnostic reasoning tasks. Domain-adapted LLMs also beat larger generic models on clinical research tasks, while agentic systems show only modest gains. Regulatory clearance pathways have not yet addressed comparative performance.
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.
Penn joined 35 universities in an amicus brief supporting Harvard’s lawsuit against a $2 billion federal research funding freeze. The brief warns that such cuts endanger basic research and innovation, as Penn itself faces over $400 million in recent funding freezes and cuts.
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Synthetic drug smuggling inside detention facilities is causing deaths and hospitalizations: Cook County Jail inmates have died from smoking drug-laced paper, and a San Diego juvenile hall faces a drug crisis involving a guard bringing drugs in a burrito, sparking a state investigation.
Relay Therapeutics reported Q4/FY 2025 results, outlined 2026 milestones for zovegalisib, and held ~$555M in cash. Initial vascular anomaly data and breast cancer triplet data are expected in 2026.
Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.
The Trump administration terminates a Medicare Part D premium subsidy program for nearly 25 million seniors, while the One Big Beautiful Bill Act triggers automatic Medicare cuts of $536 billion through 2034 and delays drug price negotiations for certain orphan drugs. Changes could raise costs for beneficiaries and delay assistance for low-income seniors.
Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.
